[Potentiation strategies].
La Presse Médicale. 2016-03-01; 45(3): 338-349
DOI: 10.1016/j.lpm.2016.02.004
Read on PubMed
1. Presse Med. 2016 Mar;45(3):338-49. doi: 10.1016/j.lpm.2016.02.004. Epub 2016
Mar 10.
[Potentiation strategies].
[Article in French]
Doumy O(1), Bennabi D(2), El-Hage W(3), Allaïli N(4), Bation R(5), Bellivier
F(4), Holtzmann J(6), Bubrovszky M(7), Camus V(3), Charpeaud T(8), Courvoisier
P(6), d’Amato T(5), Garnier M(8), Haesebaert F(5), Bougerol T(6), Lançon C(9),
Moliere F(10), Nieto I(4), Richieri R(9), Saba G(11), Courtet P(10), Vaiva G(7),
Leboyer M(11), Llorca PM(8), Aouizerate B(12), Haffen E(2).
Author information:
(1)Centre expert Dépression résistante FondaMental, CH Charles-Perrens, Pôle de
Psychiatrie générale et universitaire, 33076 Bordeaux cedex, France. Electronic
address: .
(2)Centre expert Dépression résistante FondaMental, CHU de Besançon, Service de
Psychiatrie de l’Adulte, 25030 Besançon cedex, France.
(3)Centre expert Dépression résistante FondaMental, CHU de Tours, Clinique
Psychiatrique Universitaire, 37044 Tours cedex 9, France.
(4)Centre expert Dépression résistante FondaMental, hôpital Fernand-Widal,
Service de Psychiatrie Adulte, 75010 Paris, France.
(5)Centre expert Dépression résistante FondaMental, Centre Hospitalier Le
Vinatier, Service Universitaire de Psychiatrie Adulte, BP 300 39, 69678 Bron
cedex, France.
(6)Centre expert Dépression résistante FondaMental, Hôpital Nord, CHU de
Grenoble, Service de Psychiatrie de l’adulte, CS 10217, 38043 Grenoble cedex 9,
France.
(7)Centre expert Dépression résistante FondaMental, hôpital Fontan 1, CHRU de
Lille, Service de Psychiatrie Adulte, 59037 Lille cedex, France.
(8)Centre expert Dépression résistante FondaMental, CHU de Clermont-Ferrand,
Service de Psychiatrie de l’adulte B, 63003 Clermont-Ferrand, France.
(9)Centre expert Dépression résistante FondaMental, CHU La Conception, Pôle
Psychiatrie Centre, 13005 Marseille, France.
(10)Centre expert Dépression résistante FondaMental, Département des urgences et
post-urgences psychiatrique, CHRU Lapeyronie, 34295 Montpellier cedex 5, France.
(11)Centre expert Dépression résistante FondaMental, Pôle de Psychiatrie des
hôpitaux universitaires, Henri-Mondor, Hôpital Chenevier, 94000 Créteil, France.
(12)Centre expert Dépression résistante FondaMental, CH Charles-Perrens, Pôle de
Psychiatrie générale et universitaire, 33076 Bordeaux cedex, France.
Lithium is among the most classically recommended add-on therapeutic strategy
for the management of depressive patients showing unsuccessful response to
standard antidepressant medications. The effectiveness of the add-on strategy
with lithium requires achieving plasma levels above 0.5 mEq/L. Mood-stabilizing
antiepileptic drugs such as carbamazepine, valproate derivatives or lamotrigine
have not demonstrated conclusive therapeutic effects for the management of
depressive patients showing unsuccessful response to standard antidepressant
medications. Thyroid hormones are considered among the currently recommended
add-on therapeutic strategy for the management of depressive patients showing
unsuccessful response to standard antidepressant medications. The effectiveness
of the add-on strategy with thyroid hormones requires achieving plasma
concentration of TSH close to the lower limits at the normal range (0.4 μUI/L)
or even below it. Second-generation antipsychotics such as aripiprazole or
quetiapine have consistently demonstrated significant therapeutic effects for
the management of depressive patients showing unsuccessful response to standard
antidepressant medications. Second-generation antipsychotics however require the
careful monitoring of both cardiovascular and metabolic adverse effects.
Copyright © 2016. Published by Elsevier Masson SAS.
DOI: 10.1016/j.lpm.2016.02.004
PMID: 26970936 [Indexed for MEDLINE]